Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer

Hadoux, Julien, Elisei, Rossella, Brose, Marcia S., Hoff, Ana O., Robinson, Bruce G., Gao, Ming, Jarzab, Barbara, Isaev, Pavel, Kopeckova, Katerina, Wadsley, Jonathan, Führer, Dagmar, Keam, Bhumsuk, Bardet, Stéphane, Sherman, Eric J., Tahara, Makoto, Hu, Mimi I., Singh, Ravinder, Lin, Yan, Soldatenkova, Victoria, Wright, Jennifer, Lin, Boris, Maeda, Patricia, Capdevila, Jaume, Wirth, Lori J. · 2023 · New England Journal of Medicine

Abstract

BACKGROUND: -mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear. METHODS: We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end point in the protocol-specified interim efficacy analysis was progression-free survival, assessed by blinded independent central review. Crossover to selpercatinib was permitted among patients in the control group after disease progression. Treatment failure-free survival, assessed by blinded independent central review, was a secondary, alpha-controlled end point that was to be tested only if progression-free survival was significant. Among the other secondary end points were overall response and safety. RESULTS: A total of 291 patients underwent randomization. At a median follow-up of 12 months, median progression-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 16.8 months (95% confidence interval [CI], 12.2 to 25.1) in the control group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.16 to 0.48; P<0.001). Progression-free survival at 12 months was 86.8% (95% CI, 79.8 to 91.6) in the selpercatinib group and 65.7% (95% CI, 51.9 to 76.4) in the control group. Median treatment failure-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 13.9 months in the control group (hazard ratio for disease progression, discontinuation due to treatment-related adverse events, or death, 0.25; 95% CI, 0.15 to 0.42; P<0.001). Treatment failure-free survival at 12 months was 86.2% (95% CI, 79.1 to 91.0) in the selpercatinib group and 62.1% (95% CI, 48.9 to 72.8) in the control group. The overall response was 69.4% (95% CI, 62.4 to 75.8) in the selpercatinib group and 38.8% (95% CI, 29.1 to 49.2) in the control group. Adverse events led to a dose reduction in 38.9% of the patients in the selpercatinib group, as compared with 77.3% in the control group, and to treatment discontinuation in 4.7% and 26.8%, respectively. CONCLUSIONS: -mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2309719

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 210

Metadata

Authors
Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., Führer, D., Keam, B., Bardet, S., Sherman, E. J., Tahara, M., Hu, M. I., Singh, R., Lin, Y., Soldatenkova, V., Wright, J., Lin, B., Maeda, P., Capdevila, J., & Wirth, L. J.
Venue
New England Journal of Medicine
Published
2023-11-16
Volume
389
Issue
20
Pages
1851-1861
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4387844848
Cited by
210
References
2
FWCI
34.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2309719
The paper
Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., Führer, D., Keam, B., Bardet, S., Sherman, E. J., Tahara, M., Hu, M. I., Singh, R., Lin, Y., Soldatenkova, V., . . . Wirth, L. J. (2023). Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2309719

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.